Overview

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of VX-973 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Midazolam